[A23-03] Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V
Last updated 06.07.2023
Project no.:
A23-03
Commission:
Commission awarded on 16.01.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated
Result of dossier assessment:
- Patients with treatment-naive mCRPC < 65 years: hint of minor added benefit
- Patients with treatment-naive mCRPC ≥ 65 years: hint of lesser benefit
- Patients with pretreated mCRPC: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.